Pregabalin Capsule
Product Images NDC 71205-608

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-608-60 (Pregabalin 150mg 90s)

Pregabalin 150 mg capsules label from Proficient Rx LP. The package contains 60 white hard gelatin capsules imprinted with black ink 'A011' on the cap and 'PREG 150' on the body. This is a prescription drug with NDC 71205-608-60, manufactured by Alkem Laboratories Ltd. in Mumbai, India.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula showing creatinine clearance (CLCr) calculation based on age, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph showing responder rates (%) from two clinical studies labeled Study E1 and Study E3 for Pregabalin at various dosages compared to placebo. The X-axis lists treatment groups with daily dosages and the number of participants (N). The Y-axis shows the responder rate percentage. Study E1 compares placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day dosages with BID administration. Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID. Higher responder rates with Pregabalin doses are statistically significant versus placebo, indicated by asterisks.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing median percentage seizure reduction from baseline on the y-axis and dose in mg/day of Pregabalin on the x-axis. The graph compares results from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID) with data points at doses 0 (placebo), 50, 150, 300, and 600 mg/day. Statistically significant p-values are indicated for most dose points.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg three times a day, Pregabalin 150 mg three times a day, Pregabalin 25 mg three times a day, and Placebo. The graph illustrates efficacy trends across these groups in pain improvement.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing the percent of subjects improved versus percent improvement from baseline to Week 12 BOCF between Pregabalin and Placebo groups. The vertical axis shows the percent of subjects improved, while the horizontal axis shows percent improvement from baseline. Pregabalin data is represented by a solid line, and placebo data by a dashed line.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph showing percent improved from baseline to week 16 based on the Brief Pain Inventory (BPI) for Pregabalin compared to placebo. The x-axis represents percent improved, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin and placebo, indicating higher improvement with Pregabalin over placebo across the measured range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line chart showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two curves compare Pregabalin 100 mg three times a day versus placebo regarding pain improvement percentages.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, along with a placebo group, illustrating trends in patient pain improvement across these groups.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line chart comparing the percent of patients improved relative to percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows the percent of patients improved, while the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph compares the efficacy of these dosages of Pregabalin to placebo over a range of pain improvement percentages.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for different Pregabalin daily doses (600 mg, 450 mg, 300 mg) and placebo. The graph compares pain improvement outcomes across these dose groups.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (loss to response) over 180 days. Two lines represent the groups: one for Pregabalin and one for placebo, with the Pregabalin group maintaining higher estimated survival without LTR compared to placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin showing its molecular arrangement with amino and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.